Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00286494 · ClinicalTrials.gov registry record · Phase 3
Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 493
- Enrollment target
NCT00286494: Completed Phase 3 study, sponsored by Takeda.
NCT00286494 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 493 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (36% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00286494, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 493 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), combined with pioglitazone in adults with type 2 diabetes mellitus
Primary Outcome
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 26 or final visit and glycosylated hemoglobin collected at baseline.
Interventions
- DRUG Pioglitazone
- DRUG Alogliptin and pioglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 493 participants |
| Start Date | 2006-02 |
| Est. Completion | 2007-08 |
| Phase | Phase 3 |
What the finished NCT00286494 record still lists
NCT00286494 is an interventional study that assigns participants to a tested intervention. The registered 493 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (36% lower).
The record links to 0 conditions, and to 2 interventions - of which Pioglitazone is the first listed.
NCT00286494 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00286494 about?
NCT00286494 is a clinical study titled "Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus". The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), combined with pioglitazone in adults with type 2 diabetes mellitus
What is the current status of trial NCT00286494?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 493 participants. The study started on 2006-02. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00286494?
The interventions under investigation include: Pioglitazone (DRUG), Alogliptin and pioglitazone (DRUG).
Who is sponsoring clinical trial NCT00286494?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00286494's enrollment target sits among peer trials
493 779th of 2000 higher than 1,221 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05861973 · 492 participants · NA
SMARTer Weight Loss Management
- NCT05908331 · 492 participants · NA
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
- NCT06152575 · 492 participants · Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- NCT06953089 · 492 participants · Phase 2
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia